Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical solution containing terbinafine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing terbinafine are listed in tablet, cream and spray forms. No terbinafine product of any kind is listed in solution form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Terbinafine is an allylamine antifungal, commonly compounded into topical nail solutions and lacquers, creams and oral capsules.
Terbinafine is an allylamine antifungal. It blocks squalene epoxidase, an enzyme fungi need to build ergosterol for their cell membranes; the resulting buildup of squalene is what kills the fungal cell. Manufactured terbinafine hydrochloride tablets (the former Lamisil brand and generics) are FDA-approved for onychomycosis of the toenail or fingernail caused by dermatophytes, with the label calling for lab confirmation of the infection first. Terbinafine oral granules were approved for tinea capitis in children but no granules product is currently listed on DailyMed, and over-the-counter Lamisil AT creams and sprays are sold for skin infections such as athlete's foot. Prescribers order terbinafine compounded when they want a topical nail solution or lacquer, which no manufacturer makes, a combination with another antifungal, or an oral strength or vehicle suited to a particular patient. Compounded preparations are not FDA-approved and require a prescription.
The oral label carries no boxed warning, but liver failure, sometimes fatal or requiring transplant, has occurred in people with and without prior liver disease, so oral terbinafine is contraindicated in chronic or active liver disease and liver tests are checked before and during treatment. Taste or smell loss can be severe, last over a year or be permanent; stop and talk to your prescriber or pharmacist if it starts. Other warnings cover depression, serious skin reactions, low white cells, lupus and thrombotic microangiopathy. Terbinafine inhibits CYP2D6, raising levels of tricyclics, some SSRIs, beta blockers and flecainide; cimetidine raises terbinafine levels and rifampin lowers them. Pregnancy: human data are insufficient; animal studies showed no harm. Breastfeeding: oral terbinafine reaches milk in low amounts, so watch young exclusively breastfed infants for jaundice; topical use away from the nipple is low risk. Common side effects are headache, diarrhea, rash and upset stomach. Report dark urine, pale stools or yellowed skin right away.
Terbinafine noncompetitively inhibits fungal squalene epoxidase; it is fungicidal through squalene accumulation rather than ergosterol depletion alone. Oral absorption exceeds 70 percent but first-pass metabolism limits bioavailability to about 40 percent; protein binding exceeds 99 percent. The half-life at steady state is about 36 hours with a terminal half-life of 200 to 400 hours reflecting slow release from skin, nail and fat. It is metabolized by at least seven CYP isoenzymes (mainly CYP2C9, 1A2, 3A4, 2C8 and 2C19) and inhibits CYP2D6; clearance is roughly halved in renal impairment or cirrhosis. Labeled indication (terbinafine HCl tablets): dermatophyte onychomycosis of toenail or fingernail. StatPearls lists off-label oral use in pediatric onychomycosis and tinea capitis and notes pulse regimens. Published support for topical nail terbinafine is limited: a 2025 Cureus case report describes an improvised terbinafine-in-lacquer mixture (crushed oral tablet in an OTC tolnaftate lacquer) applied to toenails, and the authors call for controlled studies of concentrations and application schedules. Dosing is per prescriber. Monitoring: transaminases at baseline and during therapy (injury clusters within the first three months), CBC if symptoms suggest dyscrasia, and discontinuation for taste or smell loss, rash or neutropenia. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin using the applicator provided or a cotton swab. Let it dry before covering. Use an accurate measuring device if your label gives a volume. Keep it away from the eyes and avoid open flame if the solution contains alcohol. Wash your hands afterward.
Topical solutions are aqueous or alcohol based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Keep the bottle tightly closed at room temperature, away from heat and flame, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)
